Cambridge, UK, 2nd April: PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today confirmed that it has entered into a commercial agreement with Addenbrooke’s hospital, part of Cambridge University Hospitals NHS Foundation Trust, to provide PredictSURE IBD™ to clinicians and gastroenterologists in the UK and Ireland.
Under the agreement, the East Midlands and East of England Genomic Laboratory Hub based at Addenbrooke’s Hospital, will manage and facilitate the fulfilment of orders of PredictSURE…
Cambridge, UK, 01 April 2019: Metrion Biosciences Ltd (“Metrion”), the specialist ion channel contract research and drug discovery company, announced today that it has completed a fully subscribed funding round on 14 March. Metrion will use the funds to support the broadening of its ion channel screening capabilities, and continued research into novel Kv1.3 inhibitors for the treatment of auto-immune conditions.
The new equity investment round was led by the recently launched o2h Ventures Therapeutics Fund, acting via Reyker Securities plc, and supported by existing shareholders…
Establishes New Clinical Advisory Board of Leading Oncology Experts
Cambridge, UK, 1 April 2019. Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing a broad pipeline of innovative treatments for cancer, today announces the appointment of Ian Smith, M.D., as Chief Medical Officer. Dr. Smith will assume responsibility for leading Artios’s overall preclinical and clinical development strategy, regulatory, and medical activities. He will work in tandem with and report directly to Niall Martin, Chief Executive Officer, and join the company’s executive leadership…
Stevenage Bioscience Catalyst (SBC) is pleased to announce that Dr Wesley Randle is to join as Chief Business Officer (CBO) in June 2019.
Dr Randle joins from UCLB, the technology transfer company of UCL and its partner NHS Trusts where he was a Senior Business Manager. Whilst at UCLB he worked closely with the UCL Technology Fund and was responsible for managing the commercialisation of IP and technology at UCL Institute of Ophthalmology and Moorfields Eye Hospital.
Prior to joining UCLB, Wesley worked in a number of early stage companies including an Imperial College regenerative medicine…
Funds will accelerate commercialization of InVisionFirstTM-Lung Liquid Biopsy test and the development of the InVision® liquid biopsy platform into new indications
Research Triangle Park, NC and Cambridge, UK, March 28, 2019 -- Inivata, a leader in liquid biopsy, today announces the completion of a Series B fundraising of $52.6m (£39.8 million).
Existing investors Woodford Patient Capital Trust, IP Group, Cambridge Innovation Capital and Johnson & Johnson Innovation – JJDC all participated in the round alongside new investor RT Ventures. The first close of the financing occurred in August…
Basel (CH) 27 March 2019 – Lonza announced today the next stage in the evolution of its market-leading GS Xceed® expression platform with the launch of GS piggyBac™, a highly efficient gene integration technology. GS piggyBac™ is capable of inserting large DNA cargos into transcriptionally active and genetically stable areas of the genome associated with highly expressed genes. Demonstrating higher yields and enhanced performance, GS piggyBac™ is well suited to support the expression of challenging proteins.
Commitment to innovation
Lonza’s GS Xceed® expression system is…
NICE issues Medtech Innovation Briefing on PredictSURE IBD™ for inflammatory bowel disease prognosis
Cambridge, UK, 28 March 2019: PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today announced that the UK's National Institute for Health and Care Excellence (NICE) has published a Medtech Innovation Briefing (MIB) on the use of PredictSURE IBD™ in the prognosis of inflammatory bowel disease.
MIBs are NICE advice designed to support NHS and social care commissioners and staff who are considering using new medical devices and other medical or diagnostic technologies. Designed to be fast, flexible…
BioIVT will contribute its assay development and validation expertise to support the consortium’s research initiatives
Westbury, NY – Mar. 25, 2019 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has joined the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium.
The FNIH Biomarkers Consortium is a public-private biomedical research partnership. It brings together members of industry, academia, nonprofit and patient advocacy organizations, and government agencies and institutes to…
Cambridge, UK, 25 March 2019: Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced it is collaborating with St George’s University Hospital, London, and the European Molecular Genetics Quality Network (EMQN), based within the Manchester Centre for Genomic Medicine at Saint Mary’s Hospital, to develop reference material for non-invasive prenatal testing (NIPT).
Well-characterized reference material that consists of matched (related) maternal and fetal DNA with a variety of chromosomal aneuploidies…
The 10th annual Babraham Investor Conference is taking place in Cambridge on 15 May 2019
Babraham 25th March 2018: Now in its 10th year, the one-day Babraham Investor Conference (BIC) will bring together like-minded investors focused on early-stage and scale-up life science and med-tech opportunities across the UK and Europe.
As well as expert-led panel discussions and sessions focused on scale-up and venture-stage growth companies, investors will hear pitches from a broad spectrum of early stage and scale-up companies seeking investment.
Taking place at the Babraham Research Campus, the…